Emilab - Company finances
|
EUR
|
2024
From: 2024-07-16
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 48,195 | 100,177 |
| Profit before tax | 35,486 | 7,763 |
| Net profit | 35,486 | 7,213 |
| Equity | 35,611 | 7,338 |
| Liabilities | 1,223 | 1,356 |
| Non-current assets | 0 | 0 |
| Current assets | 36,834 | 8,694 |
| Total assets | 36,834 | 8,694 |
|
Taxes paid
|
||
| STI taxes | 249 | 4 |
|
Financial indicators
|
||
| Revenue change y/y | - | +107.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 96.3% | 83.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 99.6% | 98.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 73.6% | 7.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 73.6% | 7.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Emilab - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-05-04 | 2025-05-31 | 72.45 |
| 2025-03-01 | 2025-03-31 | 72.45 |
| 2025-02-03 | 2025-02-28 | 7.95 |
| 2025-02-01 | 2025-02-02 | 72.45 |
| 2025-01-02 | 2025-01-31 | 64.50 |
| 2024-12-03 | 2024-12-31 | 64.50 |
| 2024-11-04 | 2024-11-30 | 64.50 |
| 2024-09-03 | 2024-09-30 | 64.50 |
Emilab - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-02-20 | 2025-02-21 | 4.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Emilab, MB (code 306947361) is a Lithuanian small partnership engaged in the manufacture of other medical and dental devices, instruments and supplies. In 2025, the latest financial year, the company generated revenue of €100.2K, up 107.9% year on year from €48.2K in 2024. Net profit in 2025 was €7.2K, compared with €35.5K in the previous year, and the profit margin decreased from 73.6% in 2024 to 7.2% in 2025. The two-year trajectory therefore shows strong sales growth but a clear decline in profitability after the exceptionally high 2024 result. At the end of 2025, total assets stood at €8.7K, equity at €7.3K and liabilities at €1.4K, indicating a lightly leveraged balance sheet. The debt-to-equity ratio was 0.18 and asset turnover was 11.52x. Return metrics were very high relative to the small equity and asset base, reflecting the limited scale of the business rather than a large balance sheet.